Organic compounds

Abstract

The present invention relates to PDEI inhibitory compounds of Formula I as described herein, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.

Description

TECHNICAL FIELD

The present invention relates to PDE1 inhibitory compounds of Formula I as described below, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them. These compounds are useful e.g., in the treatment of diseases involving disorders of the dopamine D1 receptor intracellular pathway, such as Parkinson's disease, depression, narcolepsy, psychosis, damage to cognitive function, e.g., in schizophrenia, or disorders that may be ameliorated through enhanced progesterone-signaling pathway, e.g., female sexual dysfunction.

BACKGROUND OF THE INVENTION

Eleven families of phosphodiesterases (PDEs) have been identified but only PDEs in Family I, the Ca²⁺-calmodulin-dependent phosphodiesterases (CaM-PDEs), have been shown to mediate both the calcium and cyclic nucleotide (e.g. cAMP and cGMP) signaling pathways. The three known CaM-PDE genes, PDE1A, PDE1B, and PDE1C, are all expressed in human central nervous system tissue. PDE1A is expressed in the brain with high levels in the CA1 to CA3 layers of the hippocampus and cerebellum and at a low level in the striatum. PDE1B is predominately expressed in the striatum, dentate gyrus, olfactory tract and in the prefrontal cortex colocalized with the dopamine D1 receptor. Its expression generally correlates with brain regions having high levels of dopaminergic innervation. Although PDE1B is primarily expressed in the central nervous system, it is present in neutrophils. PDE1C is more ubiquitously expressed in the brain and is expressed in the heart and vascular smooth muscle.

Cyclic nucleotide phosphodiesterases decrease intracellular cAMP and cGMP signaling by hydrolyzing these cyclic nucleotides to their respective inactive 5′-monophosphates (5′AMP and 5′GMP). CaM-PDEs play a critical role in mediating signal transduction in brain cells, particularly within an area of the brain known as the basal ganglia or striation. For example, NMDA-type glutamate receptor activation and/or dopamine D2 receptor activation result in increased intracellular calcium concentrations, leading to activation of effectors such as calmodulin-dependent kinase II (CaMKII) and calcineurin and to activation of CaM-PDEs, resulting in reduced cAMP and cGMP. Dopamine D1 receptor activation, on the other hand, leads to activation of adenylate cyclases, resulting in increased cAMP. This cyclic nucleotide in turn activate protein kinase A (PKA; cAMP-dependent protein kinase). Production of cGMP is known to occur in tissues involved in cognitive function through various stimulations such as nitric oxide production induced by high intra-cellular calcium levels and to subsequently activate protein kinase G (PKG; cGMP-dependent protein kinase). PKG and PKA phosphorylate downstream signal transduction pathway elements such as DARPP-32 (dopamine and cAMP-regulated phosphoprotein) and cAMP responsive element binding protein (CREB). Phosphorylated DARPP-32 in turn inhibits the activity of protein phosphates-1 (PP-1), thereby increasing the state of phosphorylation of substrate proteins such as progesterone receptor (PR), leading to induction of physiologic responses. D1 receptor signaling is disrupted in schizophrenia, contributing to cognitive impairment in the disease. The role of cAMP and cGMP in cognitive function has been well established in animal studies. Studies in rodents also have suggested that inducing cAMP and cGMP synthesis through activation of dopamine D1 or progesterone receptor enhances progesterone signaling associated with various physiological responses, including the lordosis response associated with receptivity to mating in some rodents. See Mani, et al., Science (2000) 287: 1053, the contents of which are incorporated herein by reference.

CaM-PDEs can therefore affect dopamine-regulated and other intracellular signaling pathways in the basal ganglia (striatum), including but not limited to nitric oxide, noradrenergic, neurotensin, CCK, VIP, serotonin, glutamate (e.g., NMDA receptor, AMPA receptor), GABA, acetylcholine, adenosine (e.g., A2A receptor), cannabinoid receptor, natriuretic peptide (e.g., ANP, BNP, CNP), DARPP-32, and endorphin intracellular signaling pathways.

Phosphodiesterase (PDE) activity, in particular, phosphodiesterase 1 (PDE1) activity, functions in brain tissue as a regulator of locomotor activity and learning and memory. PDE1 is a therapeutic target for regulation of intracellular signaling pathways, preferably in the nervous system, including but not limited to a dopamine D1 receptor, dopamine D2 receptor, nitric oxide, noradrenergic, neurotensin, CCK, VIP, serotonin, glutamate (e.g., NMDA receptor, AMPA receptor), GABA, acetylcholine, adenosine (e.g., A2A receptor), cannabinoid receptor, natriuretic peptide (e.g., ANP, BNP, CNP), endorphin intracellular signaling pathway and progesterone signaling pathway. For example, inhibition of PDE1B should act to potentiate the effect of a dopamine D1 agonist by protecting cGMP and cAMP from degradation, and should similarly inhibit dopamine D2 receptor signaling pathways, by inhibiting PDE1 activity that is a consequence of D2 receptor-mediated increases in intra-cellular calcium. Chronic elevation in intracellular calcium levels is linked to cell death in numerous disorders, particularly in neurodegerative diseases such as Alzheimer's, Parkinson's and Huntington's Diseases and in disorders of the circulatory system leading to stroke and myocardial infarction. PDE1 inhibitors are therefore potentially useful in diseases characterized by reduced dopamine D1 receptor signaling activity, such as Parkinson's disease, restless leg syndrome, depression, narcolepsy and cognitive impairment such as cognitive impairment associated with schizophrenia. PDE1 inhibitors are also useful in diseases that may be alleviated by the enhancement of progesterone-signaling such as female sexual dysfunction.

There is thus a need for compounds that selectively inhibit PDE1 activity.

SUMMARY OF THE INVENTION

The invention provides a Compound of Formula I:

wherein

• • (i) R₁ is H or C_1-4 alkyl (e.g., methyl or ethyl);
  • (ii) R₄ is H and R₂ and R₃ are independently H or C_1-6alkyl (e.g., methyl);
    • or
    • R₂ is H and R₃ and R₄ together form a di-, tri- or tetramethylene bridge (e.g., wherein the R₃ and R₄ together have the cis configuration, e.g., where the carbons carrying R₃ and R₄ have the R and S configurations, respectively);
  • (iii) R₅ is attached to one of the nitrogens on the pyrazolo portion of Formula I and is a moiety of Formula A

• • • wherein:
    • X, Y and Z are C;
    • R₈, R₉, R₁₁ and R₁₂ are H; and
    • R₁₀ is heteroaryl (e.g., pyridyl (for example pyrid-2-yl), optionally substituted with one or more halo (e.g., F or Cl), for example R₁₀ is unsubstituted pyridyl, or pyridyl substituted with halo (e.g., fluoro), for example R₁₀ is selected from a group consisting of pyridyl (for example pyrid-2-yl), 6-fluoropyrid-2-yl, 5-fluoropyrid-2-yl, 4-fluoropyrid-2-yl and 3-fluoropyrid-2-yl;
  • (iv) R₆ is ethyl or isopropyl,in free or form.

The invention further provides compounds of Formula I as follows:

• • 1.1 Formula I, wherein R₁ is H or C_1-4 alkyl (e.g., methyl);
  • 1.2 Formula I or 1.1, wherein R₁ is H;
  • 1.3 Formula I or 1.1, wherein R₁ is C_1-4 alkyl;
  • 1.4 Formula I or 1.1, wherein R₁ is methyl;
  • 1.5 Formula I, or any of 1.1-1.4, wherein R₄ is H and R₂ and R₃ are independently H or C_1-6alkyl (e.g., methyl);
  • 1.6 Formula I, or any of 1.1-1.4, wherein R₄ is H and R₂ and R₃ are both C_1-6 alkyl (e.g., R₂ and R₃ are both methyl);
  • 1.7 Formula I or any of 1.1-1.6, wherein R₁₀ is heteroaryl (e.g., pyridyl (for example pyrid-2-yl), optionally substituted with one or more halo (e.g., F or Cl), for example R₁₀ is unsubstituted pyridyl, or pyridyl substituted with halo (e.g., fluoro), for example R₁₀ is selected from a group consisting of pyridyl (for example pyrid-2-yl), 6-fluoropyrid-2-yl, 5-fluoropyrid-2-yl, 4-fluoropyrid-2-yl and 3-fluoropyrid-2-yl;
  • 1.8 Formula I or any of 1.1-1.6, wherein R₁₀ is pyridyl (e.g., pyrid-2-yl);
  • 1.9 Formula I or any of 1.1-1.6, wherein R₁₀ is 6-fluoropyrid-2-yl;
  • 1.10 Formula I or any of 1.1-1.6, wherein R₁₀ is 5-fluoropyrid-2-yl;
  • 1.11 Formula I or any of 1.1-1.6, wherein R₁₀ is 4-fluoropyrid-2-yl;
  • 1.12 Formula I or any of 1.1-1.6, wherein R₁₀ is 3-fluoropyrid-2-yl;
  • 1.13 Formula I or any of 1.1-1.12, wherein R₆ is ethyl;
  • 1.14 Formula I or any of 1.1-1.12, wherein R₆ is isopropyl;
  • 1.15 Formula I or any of 1.1-1.14, wherein R₄ is H and R₂ and R₃ are C_1-6alkyl (e.g., methyl); or
    • R₂ is H and R₃ and R₄ together form a di-, tri- or tetramethylene bridge (e.g., wherein the R₃ and R₄ together have the cis configuration, e.g., where the carbons carrying R₃ and R₄ have the R and S configurations, respectively);
  • 1.16 Formula I or any of 1.1-1.14, wherein R₄ is H and R₂ and R₃ are both methyl;
  • 1.17 Formula I or any of 1.1-1.14, wherein R₂ is H and R₃ and R₄ together form a di-, tri- or tetramethylene bridge (e.g., wherein the R₃ and R₄ together have the cis configuration, e.g., where the carbons carrying R₃ and R₄ have the R and S configurations, respectively);
  • 1.18 Formula I or any of 1.1-1.14, wherein R₂ is H and R₃ and R₄ together form a tri-methylene bridge (e.g., wherein the R₃ and R₄ together have the cis configuration, e.g., where the carbons carrying R₃ and R₄ have the R and S configurations, respectively);
  • 1.19 Formula I or any of 1.1-1.18, wherein R₆ is ethyl;
  • 1.20 Formula I or any of 1.1-1.18, wherein R₆ is isopropyl;
  • 1.21 any of formulae 1.1-1.16 and 1.19-1.20, wherein the compound is selected from a group consisting of:

• • 1.22 Any of formulae 1.1-1.15 and 1.17-1.20, wherein the compound is selected from a group consisting of:

• • 1.23 any of the preceding formulae wherein the compounds inhibit phosphodiesterase-mediated (e.g., PDE1-mediated) hydrolysis of cGMP, e.g., with an IC₅₀ of less than 1 preferably less than 10 nM, more preferably less than or equal to 5 nM in an immobilized-metal affinity particle reagent PDE assay, for example, as described in Example 4,in free or salt form.

In a particular embodiment, the invention provides a compound of Formula I(i):

wherein

• • (i) R₁ is C_1-4 alkyl (e.g., methyl or ethyl);
  • (ii) R₄ is H and R₂ and R₃ are independently C_1-6alkyl (e.g., methyl);
  • (iii) R₅ is attached to one of the nitrogens on the pyrazolo portion of Formula I and is a moiety of Formula A

• • • wherein:
    • X, Y and Z are C;
    • R₈, R₉, R₁₁ and R₁₂ are H; and
    • R₁₀ is pyridyl (for example pyrid-2-yl), substituted with one or more halo (e.g., F or Cl), for example R₁₀ is unsubstituted pyridyl, or pyridyl substituted with halo (e.g., fluoro), for example R₁₀ is selected from a group consisting of pyridyl (for example pyrid-2-yl), 6-fluoropyrid-2-yl, 5-fluoropyrid-2-yl, 4-fluoropyrid-2-yl and 3-fluoropyrid-2-yl;
  • (iv) R₆ is ethyl or isopropyl;in free or form.

If not otherwise specified or clear from context, the following terms herein have the following meanings:

• • (a) “Alkyl” as used herein is a saturated or unsaturated hydrocarbon moiety, preferably saturated, preferably having one to six carbon atoms, preferably having one to four carbon atoms, which may be linear or branched, and may be optionally mono-, di- or tri-substituted, e.g., with halogen (e.g., chloro or fluoro), hydroxy, or carboxy.
  • (b) “Aryl” as used herein is a mono or bicyclic aromatic hydrocarbon, preferably phenyl, optionally substituted, e.g., with alkyl (e.g., methyl), halogen (e.g., chloro or fluoro), haloalkyl (e.g., trifluoromethyl), hydroxy, carboxy, or an additional aryl or heteroaryl (e.g., biphenyl or pyridylphenyl).
  • (c) “Heteroaryl” as used herein is an aromatic moiety wherein one or more of the atoms making up the aromatic ring is sulfur or nitrogen rather than carbon, e.g., pyridyl or thiadiazolyl, which may be optionally substituted, e.g., with alkyl, halogen, haloalkyl, hydroxy or carboxy.

Compounds of the Invention, e.g., Compounds of Formula I or I(i), e.g., any of formulae 1.1-1.23, may exist in free or salt form, e.g., as acid addition salts. In this specification unless otherwise indicated, language such as “Compounds of the Invention” is to be understood as embracing the compounds in any form, for example free or acid addition salt form, or where the compounds contain acidic substituents, in base addition salt form. The Compounds of the Invention are intended for use as pharmaceuticals, therefore pharmaceutically acceptable salts are preferred. Salts which are unsuitable for pharmaceutical uses may be useful, for example, for the isolation or purification of free Compounds of the Invention or their pharmaceutically acceptable salts, are therefore also included.

Compounds of the Invention may in some cases also exist in prodrug form. A prodrug form is compound which converts in the body to a Compound of the Invention. For example when the Compounds of the Invention contain hydroxy or carboxy substituents, these substituents may form physiologically hydrolysable and acceptable esters. As used herein, “physiologically hydrolysable and acceptable ester” means esters of Compounds of the Invention which are hydrolysable under physiological conditions to yield acids (in the case of Compounds of the Invention which have hydroxy substituents) or alcohols (in the case of Compounds of the Invention which have carboxy substituents) which are themselves physiologically tolerable at doses to be administered. Therefore, wherein the Compound of the Invention contains a hydroxy group, for example, Compound-OH, the acyl ester prodrug of such compound, i.e., Compound-O—C(O)—C_1-4alkyl, can hydrolyze in the body to form physiologically hydrolysable alcohol (Compound-OH) on the one hand and acid on the other (e.g., HOC(O)—C_1-4alkyl). Alternatively, wherein the Compound of the Invention contains a carboxylic acid, for example, Compound-C(O)OH, the acid ester prodrug of such compound, Compound-C(O)O—C_1-4alkyl can hydrolyze to form Compound-C(O)OH and HO—C_1-4alkyl. As will be appreciated the term thus embraces conventional pharmaceutical prodrug forms.

The invention also provides methods of making the Compounds of the Invention and methods of using the Compounds of the Invention for treatment of diseases and disorders as set forth below (especially treatment of diseases characterized by reduced dopamine D1 receptor signaling activity, such as Parkinson's disease, Tourette's Syndrome, Autism, fragile X syndrome, ADHD, restless leg syndrome, depression, cognitive impairment, e.g., cognitive impairment of schizophrenia, narcolepsy and diseases that may be alleviated by the enhancement of progesterone-signaling such as female sexual dysfunction or a disease or disorder such as psychosis or glaucoma). This list is not intended to be exhaustive and may include other diseases and disorders as set forth below.

In another embodiment, the invention further provides a pharmaceutical composition comprising a Compound of the Invention, in free, pharmaceutically acceptable salt or prodrug form, in admixture with a pharmaceutically acceptable carrier.

DETAILED DESCRIPTION OF THE INVENTION

Methods of Making Compounds of the Invention

The compounds of the Invention and their pharmaceutically acceptable salts may be made using the methods as described and exemplified herein and by methods similar thereto and by methods known in the chemical art. Such methods include, but not limited to, those described below. If not commercially available, starting materials for these processes may be made by procedures, which are selected from the chemical art using techniques which are similar or analogous to the synthesis of known compounds. Various starting materials, intermediates and/or Compounds of the Invention may be prepared using methods described or similarly described in WO 2006/133261, WO 2009/075784 and/or WO 2010/065149. All references cited herein are hereby incorporated by reference in their entirety.

The Compounds of the Invention include their enantiomers, diastereoisomers and racemates, as well as their polymorphs, hydrates, solvates and complexes. Some individual compounds within the scope of this invention may contain double bonds. Representations of double bonds in this invention are meant to include both the E and the Z isomer of the double bond. In addition, some compounds within the scope of this invention may contain one or more asymmetric centers. This invention includes the use of any of the optically pure stereoisomers as well as any combination of stereoisomers.

It is also intended that the Compounds of the Invention encompass their stable and unstable isotopes. Stable isotopes are nonradioactive isotopes which contain one additional neutron compared to the abundant nuclides of the same species (i.e., element). It is expected that the activity of compounds comprising such isotopes would be retained, and such compound would also have utility for measuring pharmacokinetics of the non-isotopic analogs. For example, the hydrogen atom at a certain position on the Compounds of the Invention may be replaced with deuterium (a stable isotope which is non-radioactive). Examples of known stable isotopes include, but not limited to, deuterium, ¹³C, ¹⁵N, ¹⁸O. Alternatively, unstable isotopes, which are radioactive isotopes which contain additional neutrons compared to the abundant nuclides of the same species (i.e., element), e.g., ¹²³I, ¹³¹I, ¹²⁵I, ¹¹C, ¹⁸F, may replace the corresponding abundant species of I, C and F. Another example of useful isotope of the compound of the invention is the ¹¹C isotope. These radio isotopes are useful for radio-imaging and/or pharmacokinetic studies of the compounds of the invention. Methods of making isotopes of PDE1 inhibitors disclosed in WO 2011/043816, the contents of which are incorporated by reference in their entirety, may be used for making the isotopes of the compounds of the current invention.

Melting points are uncorrected and (dec) indicates decomposition. Temperature are given in degrees Celsius (° C.); unless otherwise stated, operations are carried out at room or ambient temperature, that is, at a temperature in the range of 18-25° C. Chromatography means flash chromatography on silica gel; thin layer chromatography (TLC) is carried out on silica gel plates. NMR data is in the delta values of major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard. Conventional abbreviations for signal shape are used. Coupling constants (J) are given in Hz. For mass spectra (MS), the lowest mass major ion is reported for molecules where isotope splitting results in multiple mass spectral peaks Solvent mixture compositions are given as volume percentages or volume ratios. In cases where the NMR spectra are complex, only diagnostic signals are reported.

Terms and Abbreviations

BuLi=n-butyllithium

Bu^tOH=tert-butyl alcohol,

CAN=ammonium cerium (IV) nitrate,

DIPEA=diisopropylethylamine,

DMF=N,N-dimethylforamide,

DMSO=dimethyl sulfoxide,

Et₂O=diethyl ether,

EtOAc=ethyl acetate,

equiv.=equivalent(s),

h=hour(s),

HPLC=high performance liquid chromatography,

LDA=lithium diisopropylamide

MeOH=methanol,

NBS=N-bromosuccinimide

NCS=N-chlorosuccinimide

NaHCO₃=sodium bicarbonate,

NH₄OH=ammonium hydroxide,

Pd₂(dba)₃=tris[dibenzylideneacetone]dipalladium(0)

PMB=p-methoxybenzyl,

POCl₃=phosphorous oxychloride,

SOCl₂=thionyl chloride,

TFA=trifluoroacetic acid,

TFMSA=trifluoromethanesulfonic acid

THF=tetrahedrofuran.

The synthetic methods in this invention are illustrated below. The significances for the R groups are as set forth above for formula I or I(i) or any of formulae 1.1-1.23, unless otherwise indicated.

In an aspect of the invention, intermediate compounds of formula IIb can be synthesized by reacting a compound of formula IIa with a dicarboxylic acid, acetic anhydride and acetic acid mixing with heat, e.g., heating to about 90° C. for about 3 hours and then cooled:

wherein R¹ is C_1-4alkyl, e.g., methyl.

Intermediate IIe can be prepared by for example reacting a compound of IIb with for example a chlorinating compound such as POCI₃, sometimes with small amounts of water and heat, e.g., heating to about 80° C. for about 4 hours and then cooled

Intermediate IId may be formed by reacting a compound of II with for example a P¹—X in a solvent such as DMF and a base such as K₂CO₃ at room temperature or with heating:

wherein P¹ is a protective group [e.g., p-methoxybenzyl group (PMB)]; X is a leaving group such as a halogen, mesylate, or tosylate. Preferably P¹ is paramethoxybenzyl (PMB) and base is potassium carbonate.

Intermediate IIe may be prepared by reacting a compound of IId with hydrazine or hydrazine hydrate in a solvent such as methanol and refluxed, e.g., for about 4 hours and then cooled:

Intermediate IVa may be formed by for example reacting a compound of IIe with POCl₃ and DMF:

wherein R¹ is as defined previously in Formula I, I(i) or any of formulae 1.1-1.23, e.g., such as a methyl group.

Intermediate IVb may be formed by reacting a compound of IVa with for example a R₅—X in a solvent such as DMF and a base such as K₂CO₃ at room temperature or with heating (Reaction 1):

Intermediate IVc may be synthesized from a compound of IVb by removing the protective group P¹ with an appropriate method. For example, if P¹ is a PMB group, then it can be removed with CAN or TFA/TFMSA at room temperature (Reaction 2):

P¹ is BOC, the compound may be deprotected by using acid such as hydrochloric acid or TFA.

Intermediate IVd can be prepared by reacting a compound of IVc with for example a chlorinating compound such as POCl₃ and refluxed for about 2 days, or heated at 150˜200° C. for about 10 min in a sealed vial with a microwave instrument and then cooled (Reaction 3):

Intermediate IVe can be formed by reacting a compound of IVd with an amino alcohol under basic condition in a solvent such as DMF and heated overnight then cooled (Reaction 4A):

Alternatively, intermediate IVe can be synthesized directly from a compound of IVc by reacting with an amino alcohol and a coupling reagent such as BOP in the presence of a base such as DBU (Reaction 4B):

wherein all the substituents are as defined previously.

Compound IVf may be formed by reacting a compound of IVe with for example a dehydrating/halogenating agent such as SOCl₂ in a solvent such as CH₂Cl₂ at room temperature overnight or heated at 35° C. for several hours, and then cooled (Reaction 5). Alternatively, Compound IVf may be prepared by reacting Compound IVe with 4-toluenesulfonyl chloride and pyridine.

Compound IVg wherein X is halogen (e.g., chloro, bromo or iodo) may be formed by reacting a compound of IVf with for example a halogenating agent such as NCS, NBS or I₂ and a base such as LDA or n-BuLi (for example, NCS in the presence of LDA) in a solvent such as THF at low temperature for several hours (Reaction 6).

Alternatively, Compound IVg may be formed by reacting a compound of IVf with for example a halogenating agent such as hexachloroethane and a base such as LiHMDS in a solvent such as THF at low temperature for several hours (Reaction 6):

Compound of Formula I or any of formulae 1.1-1.23 may be formed by reacting a compound of IVg with R₆—SH wherein R₆ is defined in Formula I, in the presence of a base (e.g., potassium carbonate) with heating, e.g., in a sealed tube and heated with stirring in a microwave reactor at 4 Barr, e.g., at 150° C. for 1 hour.

Alternatively, compound of Formula I may be formed by reacting a compound of IVf with a disulfide R₆—S—S—R₆ in the presence of a strong base, such as a lithium reagent (e.g. LiHMDS) in a solvent such as THF.

Alternatively, the Compounds of Formula I may be prepared, for example, by reacting Compound 1-A with, for example, R₅—X, in a solvent such as DMF and a base such as K₂CO₃ at room temperature or with heating:

wherein all the substitutents are as defined previously (e.g., wherein R₁-R₆ are previously defined in Formula I or I(i) or any of formulae 1.1-1.23); X is a leaving group such as a halogen, mesylate, or tosylate.

The invention therefore provides a method of preparing a compound of Formula I comprising reacting the Compound 1-A with R₅—X at room temperature or with heating. In a further embodiment, this method further comprises the presence of a base such as K₂CO₃:

In another aspect, the invention provides a method of preparing a compound of Formula I or I(i) or any of comprising reacting a compound of IVg with R₆—SH in the presence of a base (e.g., potassium carbonate) with heating, e.g., in a sealed tube and heated with stirring in a microwave reactor at 4 Barr, e.g., at 150° C. for 1 hour.

Methods of Using Compounds of the Invention

The Compounds of the Invention are useful in the treatment of diseases characterized by disruption of or damage to cAMP and cGMP mediated pathways, e.g., as a result of increased expression of PDE1 or decreased expression of cAMP and cGMP due to inhibition or reduced levels of inducers of cyclic nucleotide synthesis, such as dopamine and nitric oxide (NO). By preventing the degradation of cAMP and cGMP by PDE1, thereby increasing intracellular levels of cAMP and cGMP, the Compounds of the Invention potentiate the activity of cyclic nucleotide synthesis inducers.

The invention provides methods of treatment of any one or more of the following conditions:

• • (i) Neurodegenerative diseases, including Parkinson's disease, restless leg, tremors, dyskinesias, Huntington's disease, Alzheimer's disease, and drug-induced movement disorders;
  • (ii) Mental disorders, including depression, attention deficit disorder, attention deficit hyperactivity disorder, bipolar illness, anxiety, sleep disorders, e.g., narcolepsy, cognitive impairment, e.g., cognitive impairment of schizophrenia, dementia, Tourette's syndrome, autism, fragile X syndrome, psychostimulant withdrawal, and drug addiction;
  • (iii) Circulatory and cardiovascular disorders, including cerebrovascular disease, stroke, congestive heart disease, hypertension, pulmonary hypertension, and sexual dysfunction;
  • (iv) Respiratory and inflammatory disorders, including asthma, chronic obstructive pulmonary disease, and allergic rhinitis, as well as autoimmune and inflammatory diseases;
  • (v) diseases that may be alleviated by the enhancement of progesterone-signaling such as female sexual dysfunction;
  • (vi) a disease or disorder such as psychosis or glaucoma;
  • (vii) Any disease or condition characterized by low levels of cAMP and/or cGMP (or inhibition of cAMP and/or cGMP signaling pathways) in cells expressing PDE1; and/or
  • (viii) Any disease or condition characterized by reduced dopamine D1 receptor signaling activity,comprising administering an effective amount of a Compound of the Invention, e.g., a compound according to any of Formula I, I(i) or any of 1.1-1.23, in free,pharmaceutically acceptable salt or prodrug form, to a human or animal patient in need thereof.

In an especially preferred embodiment, the invention provides methods of treatment or prophylaxis for narcolepsy. In this embodiment, PDE 1 Inhibitors may be used as a sole therapeutic agent, but may also be used in combination or for co-administration with other active agents. Thus, the invention further comprises a method of treating narcolepsy comprising administering simultaneously, sequentially, or contemporaneously administering therapeutically effective amounts of

• • (i) a PDE 1 Inhibitor, e.g., a compound according to any of Formula I, I(i) or any of 1.1-1.23, and
  • (ii) a compound to promote wakefulness or regulate sleep, e.g., selected from (a) central nervous system stimulants-amphetamines and amphetamine like compounds, e.g., methylphenidate, dextroamphetamine, methamphetamine, and pemoline; (b) modafinil, (c) antidepressants, e.g., tricyclics (including imipramine, desipramine, clomipramine, and protriptyline) and selective serotonin reuptake inhibitors (including fluoxetine and sertraline); and/or (d) gamma hydroxybutyrate (GHB).in free, pharmaceutically acceptable salt or prodrug form, to a human or animal patient in need thereof.

In another embodiment, the invention further provides methods of treatment or prophylaxis of a condition which may be alleviated by the enhancement of the progesterone signaling comprising administering an effective amount of a Compound of the Invention, e.g., a compound according to any of Formula I or any of any of 1.1-1.23, in free, pharmaceutically acceptable salt or prodrug form, to a human or animal patient in need thereof. Disease or condition that may be ameliorated by enhancement of progesterone signaling include, but are not limited to, female sexual dysfunction, secondary amenorrhea (e.g., exercise amenorrhoea, anovulation, menopause, menopausal symptoms, hypothyroidism), pre-menstrual syndrome, premature labor, infertility, for example infertility due to repeated miscarriage, irregular menstrual cycles, abnormal uterine bleeding, osteoporosis, autoimmmune disease, multiple sclerosis, prostate enlargement, prostate cancer, and hypothyroidism. For example, by enhancing progesterone signaling, the PDE 1 inhibitors may be used to encourage egg implantation through effects on the lining of uterus, and to help maintain pregnancy in women who are prone to miscarriage due to immune response to pregnancy or low progesterone function. The novel PDE 1 inhibitors, e.g., as described herein, may also be useful to enhance the effectiveness of hormone replacement therapy, e.g., administered in combination with estrogen/estradiol/estriol and/or progesterone/progestins in postmenopausal women, and estrogen-induced endometrial hyperplasia and carcinoma. The methods of the invention are also useful for animal breeding, for example to induce sexual receptivity and/or estrus in a nonhuman female mammal to be bred.

In this embodiment, PDE 1 Inhibitors may be used in the foregoing methods of treatment or prophylaxis as a sole therapeutic agent, but may also be used in combination or for co-administration with other active agents, for example in conjunction with hormone replacement therapy. Thus, the invention further comprises a method of treating disorders that may be ameliorated by enhancement of progesterone signaling comprising administering simultaneously, sequentially, or contemporaneously administering therapeutically effective amounts of

• • (i) a PDE 1 Inhibitor, e.g., a compound according to any of Formula I or any of any of 1.1-1.23, and
  • (ii) a hormone, e.g., selected from estrogen and estrogen analogues (e.g., estradiol, estriol, estradiol esters) and progesterone and progesterone analogues (e.g., progestins)in free, pharmaceutically acceptable salt or prodrug form, to a human or animal patient in need thereof.

The invention also provides a method for enhancing or potentiating dopamine D1 intracellular signaling activity in a cell or tissue comprising contacting said cell or tissue with an amount of a Compound of the Invention, e.g., Formula I, I(i) or any of any of 1.1-1.23, sufficient to inhibit PDE1 activity.

The invention also provides a method for treating a PDE1-related, disorder, a dopamine D1 receptor intracellular signaling pathway disorder, or disorders that may be alleviated by the enhancement of the progesterone signaling pathway in a patient in need thereof comprising administering to the patient an effective amount of a Compound of the Invention, e.g., Formula I, I(i) or any of any of 1.1-1.23, in that inhibits PDE1, wherein PDE1 activity modulates phosphorylation of DARPP-32 and/or the GluR1 AMPA receptor.

In another aspect, the invention also provides a method for the treatment for glaucoma or elevated intraocular pressure comprising topical administration of a therapeutically effective amount of a phospodiesterase type I (PDE1) Inhibitor of the Invention, e.g., a compound of Formula I, I(i) or any of 1.1-1.23, in free or pharmaceutically acceptable salt form, in an opthalmically compatible carrier to the eye of a patient in need thereof. However, treatment may alternatively include a systemic therapy. Systemic therapy includes treatment that can directly reach the bloodstream, or oral methods of administration, for example.

The invention further provides a pharmaceutical composition for topical ophthalmic use comprising a PDE1 inhibitor, e.g., Formula I, I(i) or any of 1.1-1.23; for example an ophthalmic solution, suspension, cream or ointment comprising a PDE1 Inhibitor of the Invention, e.g., Formula I, I(i) or any of 1.1-1.23, in free or ophthamalogically acceptable salt form, in combination or association with an ophthamologically acceptable diluent or carrier.

Optionally, the PDE1 inhibitor may be administered sequentially or simultaneously with a second drug useful for treatment of glaucoma or elevated intraocular pressure. Where two active agents are administered, the therapeutically effective amount of each agent may be below the amount needed for activity as monotherapy. Accordingly, a subthreshold amount (i.e., an amount below the level necessary for efficacy as monotherapy) may be considered therapeutically effective and also may also be referred alternatively as an effective amount. Indeed, an advantage of administering different agents with different mechanisms of action and different side effect profiles may be to reduce the dosage and side effects of either or both agents, as well as to enhance or potentiate their activity as monotherapy.

The invention thus provides the method of treatment of a condition selected from glaucoma and elevated intraocular pressure comprising administering to a patient in need thereof an effective amount, e.g., a subthreshold amount, of an agent known to lower intraocular pressure concomitantly, simultaneously or sequentially with an effective amount, e.g., a subthreshold amount, of a PDE1 Inhibitor of the Invention, e.g., Formula I, I(i) or any of 1.1-1.23, in free or pharmaceutically acceptable salt form, such that amount of the agent known to lower intraocular pressure and the amount of the PDE1 inhibitor in combination are effective to treat the condition.

In one embodiment, one or both of the agents are administered topically to the eye. Thus the invention provides a method of reducing the side effects of treatment of glaucoma or elevated intraocular pressure by administering a reduced dose of an agent known to lower intraocular pressure concomitantly, simultaneously or sequentially with an effective amount of a PDE1 inhibitor. However, methods other than topical administration, such as systemic therapeutic administration, may also be utilized.

The optional additional agent or agents for use in combination with a PDE1 inhibitor may, for example, be selected from the existing drugs comprise typically of instillation of a prostaglandin, pilocarpine, epinephrine, or topical beta-blocker treatment, e.g. with timolol, as well as systemically administered inhibitors of carbonic anhydrase, e.g. acetazolamide. Cholinesterase inhibitors such as physostigmine and echothiopate may also be employed and have an effect similar to that of pilocarpine. Drugs currently used to treat glaucoma thus include, e.g.,

• • 1. Prostaglandin analogs such as latanoprost (Xalatan), bimatoprost (Lumigan) and travoprost (Travatan), which increase uveoscleral outflow of aqueous humor. Bimatoprost also increases trabecular outflow.
  • 2. Topical beta-adrenergic receptor antagonists such as timolol, levobunolol (Betagan), and betaxolol, which decrease aqueous humor production by the ciliary body.
  • 3. Alpha₂-adrenergic agonists such as brimonidine (Alphagan), which work by a dual mechanism, decreasing aqueous production and increasing uveo-scleral outflow.
  • 4. Less-selective sympathomimetics like epinephrine and dipivefrin (Propine) increase outflow of aqueous humor through trabecular meshwork and possibly through uveoscleral outflow pathway, probably by a beta₂-receptor agonist action.
  • 5. Miotic agents (para-sympathomimetics) like pilocarpine work by contraction of the ciliary muscle, tightening the trabecular meshwork and allowing increased outflow of the aqueous humour.
  • 6. Carbonic anhydrase inhibitors like dorzolamide (Trusopt), brinzolamide (Azopt), acetazolamide (Diamox) lower secretion of aqueous humor by inhibiting carbonic anhydrase in the ciliary body.
  • 7. Physostigmine is also used to treat glaucoma and delayed gastric emptying.

For example, the invention provides pharmaceutical compositions comprising a PDE1 Inhibitor of the Invention, e.g., Formula I, I(i) or any of 1.1-1.23, and an agent selected from (i) the prostanoids, unoprostone, latanoprost, travoprost, or bimatoprost; (ii) an alpha adrenergic agonist such as brimonidine, apraclonidine, or dipivefrin and (iii) a muscarinic agonist, such as pilocarpine. For example, the invention provides ophthalmic formulations comprising a PDE-1 Inhibitor of the Invention together with bimatoprost, abrimonidine, brimonidine, timolol, or combinations thereof, in free or ophthamalogically acceptable salt form, in combination or association with an ophthamologically acceptable diluent or carrier. In addition to selecting a combination, however, a person of ordinary skill in the art can select an appropriate selective receptor subtype agonist or antagonist. For example, for alpha adrenergic agonist, one can select an agonist selective for an alpha 1 adrenergic receptor, or an agonist selective for an alpha₂ adrenergic receptor such as brimonidine, for example. For a beta-adrenergic receptor antagonist, one can select an antagonist selective for either β₁, or β₂, or β₃, depending on the appropriate therapeutic application. One can also select a muscarinic agonist selective for a particular receptor subtype such as M₁-M₅.

The PDE 1 inhibitor may be administered in the form of an ophthalmic composition, which includes an ophthalmic solution, cream or ointment. The ophthalmic composition may additionally include an intraocular-pressure lowering agent.

In yet another example, the PDE-1 Inhibitors disclosed may be combined with a subthreshold amount of an intraocular pressure-lowering agent which may be a bimatoprost ophthalmic solution, a brimonidine tartrate ophthalmic solution, or brimonidine tartrate/timolol maleate ophthalmic solution.

In addition to the above-mentioned methods, it has also been surprisingly discovered that PDE1 inhibitors are useful to treat psychosis, for example, any conditions characterized by psychotic symptoms such as hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, e.g., schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, and mania, such as in acute manic episodes and bipolar disorder. Without intending to be bound by any theory, it is believed that typical and atypical antipsychotic drugs such as clozapine primarily have their antagonistic activity at the dopamine D2 receptor. PDE1 inhibitors, however, primarily act to enhance signaling at the dopamine D1 receptor. By enhancing D1 receptor signaling, PDE1 inhibitors can increase NMDA receptor function in various brain regions, for example in nucleus accumbens neurons and in the prefrontal cortex. This enhancement of function may be seen for example in NMDA receptors containing the NR2B subunit, and may occur e.g., via activation of the Src and protein kinase A family of kinases.

Therefore, the invention provides a new method for the treatment of psychosis, e.g., schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, and mania, such as in acute manic episodes and bipolar disorder, comprising administering a therapeutically effective amount of a phosphodiesterase-1 (PDE1) Inhibitor of the Invention, e.g., Formula I, I(i) or any of 1.1-1.23, in free or pharmaceutically acceptable salt form, to a patient in need thereof.

PDE 1 Inhibitors may be used in the foregoing methods of treatment prophylaxis as a sole therapeutic agent, but may also be used in combination or for co-administration with other active agents. Thus, the invention further comprises a method of treating psychosis, e.g., schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, or mania, comprising administering simultaneously, sequentially, or contemporaneously administering therapeutically effective amounts of:

• • (i) a PDE 1 Inhibitor of the invention, in free or pharmaceutically acceptable salt form; and
  • (ii) an antipsychotic, e.g.,
    • Typical antipsychotics, e.g.,
      • Butyrophenones, e.g. Haloperidol (Haldol, Serenace), Droperidol (Droleptan);
      • Phenothiazines, e.g., Chlorpromazine (Thorazine, Largactil), Fluphenazine (Prolixin), Perphenazine (Trilafon), Prochlorperazine (Compazine), Thioridazine (Mellaril, Melleril), Trifluoperazine (Stelazine), Mesoridazine, Periciazine, Promazine, Triflupromazine (Vesprin), Levomepromazine (Nozinan), Promethazine (Phenergan), Pimozide (Orap);
      • Thioxanthenes, e.g., Chlorprothixene, Flupenthixol (Depixol, Fluanxol), Thiothixene (Navane), Zuclopenthixol (Clopixol, Acuphase);
    • Atypical antipsychotics, e.g.,
      • Clozapine (Clozaril), Olanzapine (Zyprexa), Risperidone (Risperdal), Quetiapine (Seroquel), Ziprasidone (Geodon), Amisulpride (Solian), Paliperidone (Invega), Aripiprazole (Abilify), Bifeprunox; norclozapine,
  • in free or pharmaceutically acceptable salt form, to a patient in need thereof.

In a particular embodiment, the Compounds of the Invention are particularly useful for the treatment or prophylaxis of schizophrenia.

Compounds of the Invention, in free or pharmaceutically acceptable salt form, are particularly useful for the treatment of Parkinson's disease, schizophrenia, narcolepsy, glaucoma and female sexual dysfunction.

In still another aspect, the invention provides a method of lengthening or enhancing growth of the eyelashes by administering an effective amount of a prostaglandin analogue, e.g., bimatoprost, concomitantly, simultaneously or sequentially with an effective amount of a PDE1 inhibitor of the Invention, e.g., Formula I, I(i) or any of 1.1-1.23, in free or pharmaceutically acceptable salt form, to the eye of a patient in need thereof.

In yet another aspect, the invention provides a method for the treatment or prophylaxis of traumatic brain injury comprising administering a therapeutically effective amount of a PDE1 inhibitor of the invention, e.g., Formula I, I(i) or any of 1.1-1.23, in free or pharmaceutically acceptable salt form, to a patient in need thereof. Traumatic brain injury (TBI) encompasses primary injury as well as secondary injury, including both focal and diffuse brain injuries. Secondary injuries are multiple, parallel, interacting and interdependent cascades of biological reactions arising from discrete subcellular processes (e.g., toxicity due to reactive oxygen species, overstimulation of glutamate receptors, excessive influx of calcium and inflammatory upregulation) which are caused or exacerbated by the inflammatory response and progress after the initial (primary) injury.

The present invention also provides

• • (i) a Compound of the Invention, e.g., Formula I or any of any of 1.1-1.23 as hereinbefore described in free, pharmaceutically acceptable salt form for example for use in any method or in the treatment of any disease or condition as hereinbefore set forth,
  • (ii) the use of a Compound of the Invention, e.g., Formula I, I(i) or any of 1.1-1.23 as hereinbefore described, in free, pharmaceutically acceptable salt form, (in the manufacture of a medicament) for treating any disease or condition as hereinbefore set forth,
  • (iii) a pharmaceutical composition comprising a Compound of the Invention, e.g., Formula I, I(i) or any of 1.1-1.23 as hereinbefore described, in free, pharmaceutically acceptable salt form, in combination or association with a pharmaceutically acceptable diluent or carrier, and
  • (iv) a pharmaceutical composition comprising a Compound of the Invention, e.g., Formula I, I(i) or any of 1.1-1.23 as hereinbefore described, in free, pharmaceutically acceptable salt form, in combination or association with a pharmaceutically acceptable diluent or carrier for use in the treatment of any disease or condition as hereinbefore set forth.

Therefore, the invention provides use of a Compound of the Invention, e.g., Formula I, I(i) or any of 1.1-1.23 as hereinbefore described, in free, pharmaceutically acceptable salt form, or a Compound of the Invention in a pharmaceutical composition form, (in the manufacture of a medicament) for the treatment or prophylactic treatment of the following diseases: Parkinson's disease, restless leg, tremors, dyskinesias, Huntington's disease, Alzheimer's disease, and drug-induced movement disorders; depression, attention deficit disorder, attention deficit hyperactivity disorder, bipolar illness, anxiety, sleep disorder, narcolepsy, cognitive impairment, e.g., cognitive impairment of schizophrenia, dementia, Tourette's syndrome, autism, fragile X syndrome, psychostimulant withdrawal, drug addiction, cerebrovascular disease, stroke, congestive heart disease, hypertension, pulmonary hypertension, sexual dysfunction, asthma, chronic obstructive pulmonary disease, and/or allergic rhinitis, autoimmune disease, inflammatory diseases, female sexual dysfunction, exercise amenorrhoea, anovulation, menopause, menopausal symptoms, hypothyroidism, pre-menstrual syndrome, premature labor, infertility, irregular menstrual cycles, abnormal uterine bleeding, osteoporosis, multiple sclerosis, prostate enlargement, prostate cancer, hypothyroidism, estrogen-induced endometrial hyperplasia or carcinoma any disease or condition characterized by low levels of cAMP and/or cGMP (or inhibition of cAMP and/or cGMP signaling pathways) in cells expressing PDE1, and/or by reduced dopamine D1 receptor signaling activity; and/or any disease or condition that may be ameliorated by the enhancement of progesterone signaling.

The invention also provides use of a Compound of the Invention, in free or pharmaceutically acceptable salt form, for the manufacture of a medicament for the treatment or prophylactic treatment of:

• • a) glaucoma or elevated intraocular pressure,
  • b) psychosis, for example, any conditions characterized by psychotic symptoms such as hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, e.g., schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, and mania, such as in acute manic episodes and bipolar disorder,
  • c) traumatic brain injury.

The phrase “Compounds of the Invention” or “PDE 1 inhibitors of the Invention” encompasses any and all of the compounds disclosed herewith, e.g., a Compound of Formula I, I(i) or any of 1.1-1.23 as hereinbefore described, in free or salt form.

The words “treatment” and “treating” are to be understood accordingly as embracing prophylaxis and treatment or amelioration of symptoms of disease as well as treatment of the cause of the disease. In one embodiment, the invention provides a method for the treatment of the disease or disorder disclosed herein. In another embodiment, the invention provides a method for the prophylaxis of a disease or disorder as disclosed herein.

For methods of treatment, the word “effective amount” is intended to encompass a therapeutically effective amount to treat a specific disease or disorder.

The term “pulmonary hypertension” is intended to encompass pulmonary arterial hypertension.

The term “patient” include human or non-human (i.e., animal) patient. In particular embodiment, the invention encompasses both human and nonhuman. In another embodiment, the invention encompasses nonhuman. In other embodiment, the term encompasses human.

The term “comprising” as used in this disclosure is intended to be open-ended and does not exclude additional, unrecited elements or method steps.

Compounds of the Invention are in particular useful for the treatment of Parkinson's disease, narcolepsy and female sexual dysfunction.

Compounds of the Invention, e.g., Formula I, I(i) or any of 1.1-1.23 as hereinbefore described, in free or pharmaceutically acceptable salt form may be used as a sole therapeutic agent, but may also be used in combination or for co-administration with other active agents. For example, as Compounds of the Invention potentiate the activity of D1 agonists, such as dopamine, they may be simultaneously, sequentially, or contemporaneously administered with conventional dopaminergic medications, such as levodopa and levodopa adjuncts (carbidopa, COMT inhibitors, MAO-B inhibitors), dopamine agonists, and anticholinergics, e.g., in the treatment of a patient having Parkinson's disease. In addition, the novel PDE 1 inhibitors, e.g., as described herein, may also be administered in combination with estrogen/estradiol/estriol and/or progesterone/progestins to enhance the effectiveness of hormone replacement therapy or treatment of estrogen-induced endometrial hyperplasia or carcinoma.

Dosages employed in practicing the present invention will of course vary depending, e.g. on the particular disease or condition to be treated, the particular Compound of the Invention used, the mode of administration, and the therapy desired. Compounds of the Invention may be administered by any suitable route, including orally, parenterally, transdermally, or by inhalation, but are preferably administered orally. In general, satisfactory results, e.g. for the treatment of diseases as hereinbefore set forth are indicated to be obtained on oral administration at dosages of the order from about 0.01 to 2.0 mg/kg. In larger mammals, for example humans, an indicated daily dosage for oral administration will accordingly be in the range of from about 0.75 to 150 mg, conveniently administered once, or in divided doses 2 to 4 times, daily or in sustained release form. Unit dosage forms for oral administration thus for example may comprise from about 0.2 to 75 or 150 mg, e.g. from about 0.2 or 2.0 to 50, 75 or 100 mg of a Compound of the Invention, together with a pharmaceutically acceptable diluent or carrier therefor.

Pharmaceutical compositions comprising Compounds of the Invention may be prepared using conventional diluents or excipients and techniques known in the galenic art. Thus oral dosage forms may include tablets, capsules, solutions, suspensions and the like.

EXAMPLES

The synthetic methods for various Compounds of the Present Invention are illustrated below. The intermediates of the Compounds of the Invention as well as other compounds of the Invention (e.g., compounds of formula 1.23) and their salts may be made using the methods as similarly described below and/or by methods similar to those generally described in the detailed description and by methods known in the chemical art, particularly methods disclosed in WO 2006/133261, WO 2009/075784 and WO 2010/065149, the contents of each of which are incorporated by reference in their entirety.

Example 1

3-(ethylthio)-2-(4-(5-fluoropyridin-2-yl)benzyl)-5,7,7-trimethyl-7,8-dihydro-2H-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one

A 2 mL microwave reaction vial is charged with 3-chloro-2-(4-(5-fluoropyridin-2-yl)benzyl)-5,7,7-trimethyl-7,8-dihydro-2H-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one (160 mg, 0.36 mmol), K₂CO₃ (150 mg, 1.1 mmol), excess ethanethiol (0.6 mL) and cyclopentanol (0.5 mL). The vial is sealed and heated with stirring in a microwave reactor at 4 Barr, 150° C. for 1 hour. LCMS indicates conversion of the starting material to product. The reaction mixture is allowed to cool and was then diluted with 100 mL water, and is extracted with dichloromethane (3×30 mL). The combined organic layers are evaporated to dryness, and the residue is dissolved in 1 mL dimethylformamide, filtered, and then purified by HPLC to provide 126 mg of the product as the formate salt (74% yield) with a purity of 95%. MS (ESI) m/z 465.2 [M+H]⁺.

Example 2

3-(ethylthio)-2-(4-(6-fluoropyridin-2-yl)benzyl)-5,7,7-trimethyl-7,8-dihydro-2H-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one

A 2 mL microwave reaction vial is charged with 3-chloro-2-(4-(6-fluoropyridin-2-yl)benzyl)-5,7,7-trimethyl-7,8-dihydro-2H-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one (90 mg, 0.2 mmol), K₂CO₃ (100 mg, 0.73 mmol), excess ethanethiol (0.6 mL) and cyclopentanol (0.5 mL). The vial is sealed and heated with stirring in a microwave reactor at 4 Barr, 150° C. for 1 hour. LCMS indicates conversion of the starting material to product. The reaction mixture is allowed to cool and is then diluted with 100 mL water, and extracted with dichloromethane (3×30 mL). The combined organic layers are evaporated to dryness, and the residue is dissolved in 1 mL dimethylformamide, filtered, and then purified by HPLC to provide 14 mg of the product as the formate salt (13% yield) with a purity of >98%. MS (ESI) m/z 465.2 [M+H]⁺.

Example 3

2-(4-(6-fluoropyridin-2-yl(benzyl)-3-(isopropylthio)-5,7,7-trimethyl-7,8-dihydro-2H-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one

A 2 mL microwave reaction vial was charged with 3-chloro-2-(4-(6-fluoropyridin-2-yl)benzyl)-5,7,7-trimethyl-7,8-dihydro-2H-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one s (88 mg, 0.2 mmol), K2CO3 (160 mg, 1.2 mmol), excess propane-2-thiol (0.5 mL) and cyclopentanol (0.5 mL). The vial was sealed and heated with stirring in a microwave reactor at 4 Barr, 150° C. for 1 hour. LCMS indicates conversion of the starting material to product. The reaction mixture is allowed to cool and is then diluted with 100 mL water, and extracted with dichloromethane (3×30 mL). The combined organic layers are evaporated to dryness, and the residue is dissolved in 1 mL dimethylformamide, filtered, and then purified by HPLC to provide 58 mg of the product as the formate salt (55% yield) with a purity of 96.4%. MS (ESI) m/z 479.3 [M+H]⁺.

Example 3-A

(6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(ethylthio)-2-(4-(6-fluoropyridin-2-yl)benzyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one

A 2 mL microwave reaction vial is charged with 6aR,9aS)-5,6a,7,8,9,9a-hexahydro-3-chloro-5-methyl-2-(4-(6-fluoropyridin-2-yl)benzyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one (45 mg, 0.1 mmol), K₂CO₃ (48 mg, 0.35 mmol), excess ethanethiol (0.6 mL) and cyclopentanol (0.5 mL). The vial is sealed and heated with stirring in a microwave reactor at 150° C. for 1 hour. LCMS indicates conversion of the starting material to product. The reaction mixture is allowed to cool and is then diluted with 100 mL water, and extracted with dichloromethane (3×30 mL). The combined organic layers are evaporated to dryness, and the residue is dissolved in 1 mL dimethylformamide, filtered, and then purified by HPLC to provide 32 mg of the product as the formate salt (61% yield) with a purity of >99%. MS (ESI) m/z 477.1 [M+H]⁺.

Example 3-B

(6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(isopropylthio)-2-(4-(6-fluoropyridin-2-yl)benzyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one

A 2 mL microwave reaction vial is charged with 6aR,9aS)-5,6a,7,8,9,9a-hexahydro-3-chloro-5-methyl-2-(4-(6-fluoropyridin-2-yl)benzyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one (150 mg, 0.33 mmol), K₂CO₃ (270 mg, 1.95 mmol), excess propane-2-thiol (0.5 mL) and cyclopentanol (0.5 mL). The vial is sealed and heated with stirring in a microwave reactor at 150° C. for 1 hour. LCMS indicates conversion of the starting material to product. The reaction mixture is allowed to cool and is then diluted with 100 mL water, and extracted with dichloromethane (3×30 mL). The combined organic layers are evaporated to dryness, and the residue is dissolved in 1 mL dimethylformamide, filtered, and then purified by HPLC to provide 122 mg of the product as the formate salt (69% yield) with a purity of 98%. MS (ESI) m/z 491.2 [M+H]⁺.

Example 4

Measurement of PDE1B Inhibition In Vitro Using IMAP Phosphodiesterase Assay Kit

Phosphodiesterase 1B (PDE1B) is a calcium/calmodulin dependent phosphodiesterase enzyme that converts cyclic guanosine monophosphate (cGMP) to 5′-guanosine monophosphate (5′-GMP). PDE1B can also convert a modified cGMP substrate, such as the fluorescent molecule cGMP-fluorescein, to the corresponding GMP-fluorescein. The generation of GMP-fluorescein from cGMP-fluorescein can be quantitated, using, for example, the IMAP (Molecular Devices, Sunnyvale, Calif.) immobilized-metal affinity particle reagent.

Briefly, the IMAP reagent binds with high affinity to the free 5′-phosphate that is found in GMP-fluorescein and not in cGMP-fluorescein. The resulting GMP-fluorescein—IMAP complex is large relative to cGMP-fluorescein. Small fluorophores that are bound up in a large, slowly tumbling, complex can be distinguished from unbound fluorophores, because the photons emitted as they fluoresce retain the same polarity as the photons used to excite the fluorescence.

In the phosphodiesterase assay, cGMP-fluorescein, which cannot be bound to IMAP, and therefore retains little fluorescence polarization, is converted to GMP-fluorescein, which, when bound to IMAP, yields a large increase in fluorescence polarization (Δmp) Inhibition of phosphodiesterase, therefore, is detected as a decrease in Δmp.

Enzyme Assay

Materials: All chemicals are available from Sigma-Aldrich (St. Louis, Mo.) except for IMAP reagents (reaction buffer, binding buffer, FL-GMP and IMAP beads), which are available from Molecular Devices (Sunnyvale, Calif.).

Assay: The following phosphodiesterase enzymes may be used: 3′,5′-cyclic-nucleotide-specific bovine brain phosphodiesterase (Sigma, St. Louis, Mo.) (predominantly PDE1B) and recombinant full length human PDE1A and PDE1B (r-hPDE1A and r-hPDE1B respectively) which may be produced e.g., in HEK or SF9 cells by one skilled in the art. The PDE1 enzyme is reconstituted with 50% glycerol to 2.5 U/ml. One unit of enzyme will hydrolyze 1.0 μmole of 3′,5′-cAMP to 5′-AMP per min at pH 7.5 at 30° C. One part enzyme is added to 1999 parts reaction buffer (30 μM CaCl₂, 10 U/ml of calmodulin (Sigma P2277), 10 mM Tris-HCl pH 7.2, 10 mM MgCl₂, 0.1% BSA, 0.05% NaN₃) to yield a final concentration of 1.25 mU/ml. 99 μl of diluted enzyme solution is added into each well in a flat bottom 96-well polystyrene plate to which 1 μl of test compound dissolved in 100% DMSO is added. The compounds are mixed and pre-incubated with the enzyme for 10 min at room temperature.

The FL-GMP conversion reaction is initiated by combining 4 parts enzyme and inhibitor mix with 1 part substrate solution (0.225 μM) in a 384-well microtiter plate. The reaction is incubated in dark at room temperature for 15 min. The reaction is halted by addition of 60 μl of binding reagent (1:400 dilution of IMAP beads in binding buffer supplemented with 1:1800 dilution of antifoam) to each well of the 384-well plate. The plate is incubated at room temperature for 1 hour to allow IMAP binding to proceed to completion, and then placed in an Envision multimode microplate reader (PerkinElmer, Shelton, Conn.) to measure the fluorescence polarization (Δmp).

A decrease in GMP concentration, measured as decreased Δmp, is indicative of inhibition of PDE activity. IC₅₀ values are determined by measuring enzyme activity in the presence of 8 to 16 concentrations of compound ranging from 0.0037 nM to 80,000 nM and then plotting drug concentration versus ΔmP, which allows IC₅₀ values to be estimated using nonlinear regression software (XLFit; IDBS, Cambridge, Mass.).

The Compounds of the Invention are tested in an assay as described or similarly described herein for PDE1 inhibitory activity. The exemplified compounds of the invention (e.g. compounds of Examples 1-3, 3-A, 3-B or formula 1.22 and 1.23) generally have IC₅₀ values of less than 1 μM, e.g., some less than 10 nM, some less than or equal to 5 nM as shown below.

	Example	r-hPDE1A - IC50 (nM)	r-hPDE1B - IC50 (μM)
	1	2.7	11
	2	1	4
	3	5	3
	3-A	1.5	27
	3-B	6	nd*
	*nd = not determined

Example 5

PDE1 Inhibitor Effect on Sexual Response in Female Rats

The effect of PDE1 inhibitors on Lordosis Response in female rats may be measured as described in Mani, et al., Science (2000) 287: 1053. Ovariectomized and cannulated wild-type rats are primed with 2 μg estrogen followed 24 hours later by intracerebroventricular (icv) injection of progesterone (2 μg), PDE1 inhibitors of the present invention (0.1 mg, 1.0 mg or 2.5 mg) or sesame oil vehicle (control). The rats may be tested for lordosis response in the presence of male rats. Lordosis response is quantified by the lordosis quotient (LQ=number of lordosis/10 mounts×100).

Example 6

Novel Object Recognition Assay

To measure the cognition-enhancing effects of the compounds of the invention, the candidate compounds may be evaluated in a Novel Object Recognition (NOR) assay. This assay protocol is described in detail in Ennaceur et al., Behav. Brain Res. (1988) 31:47-59 and Prickaerts et al., Eur. J. Pharmacol. (1997) 337:125-136, the contents of each of which are incorporated by reference in their entirety. In this protocol, the rats are introduced to a chamber at time T1 and allowed to interrogate two identical “familiar objects” for six minutes. Twenty four hours later, they are re-introduced to this chamber, where one of the familiar objects has been replaced with a novel object. The “discrimination index”, a measure of the time spent in close proximity to the novel over the familiar object, may then be measured. Since rodents will forget the original experience at T1 within 4 hours, this test with a 24 h interval is a measure of strong cognitive enhancement.

This assay protocol can be modified in order to evaluate different phases of memory. There are three general phases of memory, namely, acquisition, consolidation and retrieval. In this modified protocol, the rats may be dosed with the candidate compound two hours before T1 and tested 24 h later, without additional dosing. This is a test of the acquisition process. In addition, administration at various other times after the T1 test may be done to understand the compound's effectiveness in memory consolidation and recall. Specifically, these dosing times represent acquisition (T1−2 h), early consolidation (T1+0.1 h), late consolidation (T1+3 h), and retrieval (T2−2 h).

Using the protocol described above or similarly described above, the compound of Example 1 is shown to be active versus vehicle at p<0.01 at a dose of 0.3 mg/Kg PO when administering to a rat 2 hours before T1.

Example 7

Haloperidol-Induced Induced Catalepsy Model

To evaluate the potential beneficial effects to motor defects present in schizophrenics treated with typical and atypical antipsychotic agents and in Parkinson's disease patients, the compounds of the invention may be tested in a reversal of catalepsy model in which motor freezing, or catalepsy, is induced by potent dopamine D2 receptor antagonists such as haloperidol or risperidone. The method uses the “bar grip test”, in which the front paws of the mouse are placed so as to grip a 3 mm-diameter, suspended wooden bar. A “step down latency” is measured by recording the time until the mouse removes its paws from the wooden bar to the floor surface. Catalepsy is a freezing of the musculature that prevents the mouse from moving off the bar. Reduction in the catalepsy induced in this model will indicate that the compound will have a beneficial effect both in schizophrenia where extra-pyramidal side effects are frequent and in Parkinson's disease.

A total of seventeen (17) eight week-old, male, C57BL/6 mice (Jackson Laboratories) are used in a typical experiment testing the effect of the compound of Example 1 or 2. Mice are divided into six (6) groups (N=2 for vehicle group; N=3 mice/drug-treated group), receiving the following treatments: Vehicle alone, haloperidol alone (3 mg/kg PO), Compound of Example 1 or 2 alone (Mid-range dose, PO), haloperidol+Compound of Example 1 or 2 (Low-range dose, PO), haloperidol+Compound of Example 1 or 2 (Mid-range dose, PO), or haloperidol+Compound of Example 1 or 2 (High-range dose, PO). A catalepsy score is recorded for each mouse at 2, 3, 4 and 6 hours after administration of drugs. The chamber used for measuring catalepsy is comprised of a Plexiglas cage outfitted with a 3 mm-diameter wooden bar fixed horizontally 4 cm above the floor of cage. For each test session, both forepaws of the mouse are placed on the bar while the hind paws are on the Plexiglas floor. The latency until the mouse steps both paws down from the bar to the floor surface (i.e., step down latency) is recorded up to 120 sec. If the mouse steps off immediately (less than 10 sec after placement), another attempt is made up to a maximum of 10 attempts. If none of the 10 attempts are beyond 10 sec, the longest duration recorded is used as the catalepsy score. Otherwise, the initial cataleptic duration (>10 sec) is recorded during the 120 sec testing time. Mean step down latency is calculated for each treatment group. The effect of the compound of Example 1 or 2 on step down latency after haloperidol treatment is statistically evaluated by comparing group differences by analysis of variance (ANOVA, F_5,16) followed by application of Newman-Keuls post-hoc multiple comparison tests at each time point across all doses tested.

By using the protocol described or similarly described in this example, the experiment shows that the compounds of Example 1 and Example 2 are active in a catalepsy model with a minimal dose of <0.1 mg/Kg.

Claims

1. A compound selected from:

2. The compound according to claim 1, selected from

3. The compound according to claim 1, wherein the compound is

4. A pharmaceutical composition comprising the compound according to claim 1, in free or pharmaceutically acceptable salt form, in combination or association with a pharmaceutically acceptable diluent or carrier.

5. A pharmaceutical composition comprising the compound according to claim 3, in free or pharmaceutically acceptable salt form, in combination or association with a pharmaceutically acceptable diluent or carrier.